Literature DB >> 34934927

A mechanistic basis for the malignant progression of salivary gland tumors.

Sachiko Taniguchi1, Yuya Tanaka1, Ajit Elhance1, Naoki Oshimori1,2,3,4.   

Abstract

Salivary gland tumors are diverse neoplasms, likely reflecting differences in the tissue- and cell-of-origin. 80%-90% of tumors arising in the sublingual gland (SLG) are malignant, whereas the other major glands often form benign tumors. Owing to the lack of experimental models to explore the etiology of salivary gland tumors, the cellular and molecular bases of malignancy remain unknown. Here, we generated a murine model of HRASG12V-driven salivary gland tumors amenable to examine tumor onset and malignant progression. We found that HMGA2 marks the tumor onset, and transformed-SOX2+ stem/progenitor cells expand exclusively in SLG tumors. Lineage tracing experiments showed that SLG tumor cells undergo an extensive epithelial-mesenchymal transition (EMT) and TGF-β-responding tumor cells are a source of mesenchymal tumor cells invading the surrounding stroma. This study advances our understanding of the mechanistic basis of salivary gland malignancy and may help combat this highly heterogeneous cancer.
© 2021 The Author(s).

Entities:  

Keywords:  Biological sciences; Cancer; Cell biology; Endocrinology

Year:  2021        PMID: 34934927      PMCID: PMC8661530          DOI: 10.1016/j.isci.2021.103508

Source DB:  PubMed          Journal:  iScience        ISSN: 2589-0042


  45 in total

Review 1.  SOX2 in development and cancer biology.

Authors:  Daniel Novak; Laura Hüser; Jonathan J Elton; Viktor Umansky; Peter Altevogt; Jochen Utikal
Journal:  Semin Cancer Biol       Date:  2019-08-11       Impact factor: 15.707

2.  Rapid functional dissection of genetic networks via tissue-specific transduction and RNAi in mouse embryos.

Authors:  Slobodan Beronja; Geulah Livshits; Scott Williams; Elaine Fuchs
Journal:  Nat Med       Date:  2010-06-06       Impact factor: 53.440

3.  HMGA2 is a specific immunohistochemical marker for pleomorphic adenoma and carcinoma ex-pleomorphic adenoma.

Authors:  Jeffrey K Mito; Vickie Y Jo; Simion I Chiosea; Paola Dal Cin; Jeffrey F Krane
Journal:  Histopathology       Date:  2017-07-05       Impact factor: 5.087

4.  Ras in cancer and developmental diseases.

Authors:  Alberto Fernández-Medarde; Eugenio Santos
Journal:  Genes Cancer       Date:  2011-03

5.  Tumor-initiating cells establish an IL-33-TGF-β niche signaling loop to promote cancer progression.

Authors:  Sachiko Taniguchi; Ajit Elhance; Avery Van Duzer; Sushil Kumar; Justin J Leitenberger; Naoki Oshimori
Journal:  Science       Date:  2020-07-17       Impact factor: 47.728

6.  Stem cell self-renewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: clues for diagnosis.

Authors:  Hiroshi Yamazaki; Taisuke Mori; Masaki Yazawa; Akiko M Maeshima; Fumihiko Matsumoto; Seiichi Yoshimoto; Yoshihide Ota; Akihiro Kaneko; Hitoshi Tsuda; Yae Kanai
Journal:  Lab Invest       Date:  2013-10-21       Impact factor: 5.662

Review 7.  Contextual determinants of TGFβ action in development, immunity and cancer.

Authors:  Charles J David; Joan Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2018-07       Impact factor: 94.444

8.  Periderm prevents pathological epithelial adhesions during embryogenesis.

Authors:  Rebecca J Richardson; Nigel L Hammond; Pierre A Coulombe; Carola Saloranta; Heidi O Nousiainen; Riitta Salonen; Andrew Berry; Neil Hanley; Denis Headon; Riitta Karikoski; Michael J Dixon
Journal:  J Clin Invest       Date:  2014-08-18       Impact factor: 14.808

9.  Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition.

Authors:  Sylvie Thuault; Ulrich Valcourt; Maj Petersen; Guidalberto Manfioletti; Carl-Henrik Heldin; Aristidis Moustakas
Journal:  J Cell Biol       Date:  2006-07-10       Impact factor: 10.539

10.  The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation.

Authors:  Andrean L Simons; Ping Lu; Katherine N Gibson-Corley; Robert A Robinson; David K Meyerholz; John D Colgan
Journal:  Lab Invest       Date:  2013-04-22       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.